Lunai shares rise 41.32% intraday after acquiring CNS drug assets from Clemann Group for $20 million.

Lunai Bioworks surged 41.32% in intraday trading, driven by the announcement of a $20 million strategic acquisition of the Clemann Group's blood-brain barrier delivery technology and CNS Alzheimer's drug assets at a fixed conversion price of $1.50 per share to address key bottlenecks in CNS drug development. The clinical-stage biotechnology company, which operates through the RENB, BioSymetrics, and RENC divisions, specializes in AI-driven drug discovery, diagnostics, and bio-defense products focused on precision medicine applications.